Cell Processing revenue up 7% sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12% over prior year to $73.5 million

GAAP gross margin of 60% and non-GAAP adjusted gross margin of 63% for the fourth quarter

GAAP net loss from continuing operations of $2.0 million and non-GAAP adjusted EBITDA of $4.0 million, or 18% of total revenue for the fourth quarter

Expects 2025 Cell Processing revenue of $86.5 to $89.0 million, up 18% to 21% over 2024 and total revenue of $95.5 to $99.0 million, up 16% to 20% over 2024

Conference call begins at 8:00 a.m. Eastern time today

BOTHELL, Wash. (March 3, 2025) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (“CGT”) market, today announces financial results for the fourth quarter and year ended December 31, 2024, and introduces 2025 financial guidance.

Roderick de Greef, Chairman and CEO, commented, “This past year was a pivotal one for BioLife as we cemented our position as a leading pure play enabler of cell and gene therapies. We delivered five consecutive quarters of revenue growth in our cell processing platform, exceeding expectations and outperforming our raised full year guidance. At the same time, we remained focused on optimizing our portfolio – divesting non-core product lines to drive gross margin and adjusted EBITDA margin expansion from continuing operations. This work culminated in the completed sales of our freezer and biostorage businesses, bolstering our year-end cash position to more than $100 million to fuel our growth objectives.

“With this foundation in place, we enter 2025 with streamlined operations focused on our proprietary, high-growth, high-margin products, positioning us to deliver continued revenue growth and profitability. We expect 2025 cell processing revenue to grow 18% to 21%, a meaningful acceleration over 2024, and we see a significant opportunity to deepen relationships with our biopreservation customers, leveraging cross-selling to increase adoption of our broader cell processing product lines. By ultimately integrating these tools into approved therapies, we have the potential to increase our revenue per dose by two to three-fold compared to our biopreservation media alone. Our focus remains on strategically enhancing our cell processing portfolio, both organically and inorganically, to strengthen our market leadership and continue delivering long-term value for our stakeholders,” added de Greef.

•Processed 19 new U.S. FDA Master File cross references for our biopreservation media, bringing the total processed in 2024 to 69 and the cumulative total to 769.

•Our biopreservation media was embedded in 17 unique approved cell and gene therapies as of December 31, 2024, with an expectation that 8 additional approvals, geographic expansions or new indications will occur in the next 12 months. There was one additional geographic expansion for an existing approved therapy in the fourth quarter.

•On November 12, 2024, we completed the sale of SciSafe Holdings, Inc. ("SciSafe"), a previously wholly owned biostorage and services subsidiary, for approximately $73.0 million in cash. On November 14, 2024, we completed the sale of Arctic Solutions, Inc. (doing business as Custom Biogenic Systems or “CBS”), a previously wholly owned freezer subsidiary for approximately $6.1 million in cash.

BioLife Solutions is presenting various financial metrics under U.S. generally accepted accounting principles (GAAP) and as adjusted (non-GAAP). In addition, BioLife Solutions is presenting Global Cooling, Inc., SciSafe, and CBS as discontinued operations for all periods presented within the Consolidated Balance Sheets and Consolidated Statements of Operations. The Consolidated Statements Of Comprehensive Loss, Consolidated Statements of Shareholders' Equity, and Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted.

•Total revenue for the fourth quarter of 2024 was $22.7 million, an increase of $5.3 million, or 31%, from $17.4 million for the fourth quarter of 2023.

◦Cell Processing platform revenue was $20.3 million, up $5.5 million, or 37%, over the same period in 2023, and up 7% sequentially over the third quarter of 2024.

◦Evo and Thaw platform revenue was $2.4 million, a decrease of $0.2 million, or 8%, from the same period in 2023.

•Total revenue for 2024 was $82.3 million, an increase of 8% from $75.9 million for 2023.

◦Cell Processing platform revenue was $73.5 million, up $7.8 million, or 12%, from 2023.

◦Evo and Thaw platform revenue was $8.7 million, a decrease of $1.4 million, or 14%, from 2023.

•Gross margin (GAAP) for the fourth quarter of 2024 was 60% compared with 53% for the fourth quarter of 2023. Adjusted gross margin (non-GAAP) for the fourth quarter of 2024 was 63% compared with 63% for the fourth quarter of 2023.

•Gross margin (GAAP) for 2024 was 62% compared with 57% for 2023. Adjusted gross margin (non-GAAP) for 2024 was 66% compared with 63% for 2023.

•Operating loss (GAAP) for the fourth quarter of 2024 was $2.1 million, compared with $7.6 million for the fourth quarter of 2023. Adjusted operating loss (non-GAAP) for the fourth quarter of 2024 was $0.7 million compared with $5.1 million for the fourth quarter of 2023.

•Operating loss (GAAP) for 2024 was $7.1 million, compared with $23.4 million for 2023. Adjusted operating loss (non-GAAP) for 2024 was $2.8 million compared with $15.5 million for 2023.

•Net loss (GAAP) for the fourth quarter of 2024 was $2.0 million, compared with $7.2 million for the fourth quarter of 2023. Adjusted net loss (non-GAAP) for the fourth quarter of 2024 was $0.8 million compared with $4.7 million for the fourth quarter of 2023.

•Net loss (GAAP) for 2024 was $11.4 million, compared with $18.4 million for 2023. Adjusted net loss (non-GAAP) for 2024 was $3.0 million compared with $15.6 million for 2023.

•Loss per share (GAAP) for the fourth quarter of 2024 was $0.04, compared with $0.16 for the fourth quarter of 2023.

•Loss per share (GAAP) for 2024 was $0.25, compared with $0.42 for 2023.

•Adjusted EBITDA, a non-GAAP measure, for the fourth quarter of 2024 was $4.0 million, or 18% of revenue, compared with $3.7 million, or 21% of revenue, for the fourth quarter of 2023.

•Adjusted EBITDA, a non-GAAP measure, for 2024 was $15.6 million, or 19% of revenue, compared with $11.4 million, or 15% of revenue, for 2023.

•Cash, cash equivalents, and marketable securities as of December 31, 2024, were $109.2 million. The Company received net proceeds of $71.3 million and $3.4 million in cash from the sales of SciSafe and CBS, respectively, during November 2024.

2025 Revenue Guidance

BioLife Solutions is introducing 2025 revenue guidance of $95.5 million to $99.0 million, representing growth of 16% to 20% compared with 2024. This is based on expectations for our Cell Processing platform and our evo and Thaw platform, as follows:

•Cell Processing platform: $86.5 million to $89.0 million, reflecting year-over-year growth of 18% to 21%.

•evo and Thaw platform: $9.0 million to $10.0 million, reflecting year-over-year growth of 3% to 15%.

Management expects 2025 gross margin (GAAP) in the low 60% range, adjusted gross margin (non-GAAP) in the mid-60% range, reduction in net loss (GAAP), and continued expansion of adjusted EBITDA margin (non-GAAP).

Management will discuss the Company's financial results, provide a general business update and answer questions during a conference call and live webcast today at 8:00 a.m. ET (5:00 a.m. PT).

To access the webcast, log onto the Investor Relations page of BioLife's website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers. A webcast replay will be available approximately two hours after the call ends and will be archived on https://investors.biolifesolutions.com for 90 days.

BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” "intend," “expects,” "continue," “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

At the Company

Troy Wichterman

Chief Financial Officer

(425) 402-1400

twichterman@biolifesolutions.com

Investors

Alliance Advisors IR

Jody Cain

(310) 691-7100

jcain@allianceadvisors.com

    

			Three Months Ended December 31,												Year Ended December 31,
(In thousands, except per share and share data)			2024						2023						2024						2023
Product revenue			$	21,245					$	15,450					$	76,028					$	68,968
Service revenue			40						65						160						349
Rental revenue			1,428						1,875						6,066						6,538
Total product, rental, and service revenue			22,713						17,390						82,254						75,855
Costs and operating expenses:
Cost of product, rental, and service revenue (exclusive of Intangible asset amortization)			$	8,482					$	7,642					$	28,583					$	29,922
General and administrative			11,501						11,689						40,541						43,264
Sales and marketing			2,244						1,763						9,610						12,709
Research and development			1,915						3,060						7,912						12,073
Asset impairment charges			—						—						—						—
Intangible asset amortization			683						688						2,737						3,520
Change in fair value of contingent consideration			—						(415)						—						(2,193)
Total operating expenses			24,825						24,427						89,383						99,295
Operating loss			(2,112)						(7,037)						(7,129)						(23,440)
Other (expense) income:
Change in fair value of investments			—						—						(4,074)						—
Interest expense, net			(24)						(429)						(719)						(1,449)
Other income			1						217						497						1,303
Gain on settlement of Global Cooling escrow			—						—						—						5,115
Total other (expense) income, net			(23)						(212)						(4,296)						4,969
Loss before income tax benefit (expense)			(2,135)						(7,249)						(11,425)						(18,471)
Income tax benefit			131						46						38						24
(Loss) income from continuing operations			$	(2,004)					$	(7,203)					$	(11,387)					$	(18,447)
Discontinued operations:
Income (loss) from discontinued operations			14,584						(7,750)						(8,665)						(49,362)
Income tax expense			(122)						(3)						(132)						(193)
Income (loss) from discontinued operations			$	14,462					$	(7,753)					$	(8,797)					$	(49,555)
Net income (loss)			$	12,458					$	(14,956)					$	(20,184)					$	(68,002)
Net income (loss) per share - Basic
Continuing operations			$	(0.04)					$	(0.16)					$	(0.25)					$	(0.42)
Discontinued operations			$	0.31					$	(0.17)					$	(0.19)					$	(1.13)
Net income (loss)			$	0.27					$	(0.33)					$	(0.44)					$	(1.55)
Net income (loss) per share - Diluted
Continuing operations			$	(0.04)					$	(0.16)					$	(0.25)					$	(0.42)
Discontinued operations			$	0.30					$	(0.17)					$	(0.19)					$	(1.13)

# # #